Litcius/Paper detail

Prevalence, clinical significance, and persistence of autoantibodies in COVID-19

Se Ju Lee, Taejun Yoon, Jang Woo Ha, Jin Nam Kim, Ki Hyun Lee, Jung Ah Lee, Chang Hyup Kim, Sang‐Won Lee, Jung Ho Kim, Jin Young Ahn, Nam Su Ku, Jun Yong Choi, Joon‐Sup Yeom, Su Jin Jeong

2023Virology Journal23 citationsDOIOpen Access PDF

Abstract

BACKGROUND: Interest in complications and sequelae following Coronavirus disease 2019 (COVID-19) is increasing. Several articles have reported COVID-19-associated autoimmune diseases and the association between autoantibodies and the severity of COVID-19. Thromboembolic complications are frequent in patients with COVID-19, and the anti-phospholipid antibodies (aPL) is frequently detected. We conducted this study to investigate the prevalence, clinical significance, and persistence of anti-nuclear antibodies (ANA) and aPLs in COVID-19. METHODS: We enrolled patients diagnosed with COVID-19 with oxygen demand and admitted to a tertiary hospital in South Korea between July 2020 and March 2022. ANA and aPLs levels were assessed using an immunoassay kit. RESULTS: A total of 248 patients were enrolled in the study. Among them, five patients were ANA-positive, and 41 were aPL-positive (IgM anti-cardiolipin (aCL) antibody in seven patients, IgG aCL in seven patients, IgM anti-β2Glycoprotein1 antibody (aβ2-GPI) in 32 patients, and IgG aβ2-GPI in one patient). Two of five ANA-positive patients, 13 of 32 IgM aβ2-GPI-positive patients, 5 of 7 IgM aCL-positive patients, and 2 of 7 IgG aCL-positive patients were eligible for follow-up analysis, and 100%, 69.2%, 40%, and 50% of the patients remained autoantibody-positive, respectively. There were no differences in clinical outcomes between the autoantibody-positive and autoantibody-negative groups, except for the IgG aCL group showing a tendency for worse outcomes. CONCLUSION: A significant proportion of COVID-19 patients with oxygen demand were autoantibody-positive, and autoantibodies persisted for several months after symptom onset. Whether these autoantibodies are related to long-term sequelae in COVID-19 patients requires further investigation.

Topics & Concepts

AutoantibodyMedicineAntibodyClinical significanceInternal medicineImmunologyCoronavirus disease 2019 (COVID-19)SerologyGastroenterologyDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesHeparin-Induced Thrombocytopenia and ThrombosisDermatological and COVID-19 studies
Prevalence, clinical significance, and persistence of autoantibodies in COVID-19 | Litcius